INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 427m ago
HOUSE PTR27m ago
SEC 13F26m ago
ROBINHOOD CHAIN26m ago
Corporate insider
AW

Albers Jeffrey W.

DirectorCIK 0001638474

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 3
Max Insider Score26
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$52K
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Director · Aug 10, 2026
23
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$522K
5,000 sh
Aug 7, 2026
Aug 10, 2026
traded Aug 7, 2026
+3d
SEC FORM 4

Evidence

19
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$835K
8,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

26
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.05M
10.0K sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

3
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence